{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:03:14Z","timestamp":1789599794488,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Permanent pacemaker implantation (PPI) combined with hypertension leads to a higher risk of new-onset atrial fibrillation (NOAF) for patients. Hence, it is essential to study how to reduce this risk. Currently, the effects of the two common anti-hypertensive drugs, angiotensin-converting enzyme inhibitors (ACEI)\/angiotensin receptor blockers (ARB) and calcium channel blockers (CCB), on the risk of NOAF for such patients remain unknown. This study aimed to investigate this association.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This single-center retrospective study included hypertensive patients with PPI and without prior history of AF\/atrial flutter, heart valve disease, hyperthyroidism, etc. Patients were classified into ACEI\/ARB group and CCB group based on their exposure drug information. The primary outcome was NOAF events that occurred within 12 months after PPI. The secondary efficacy assessments were the changes from baseline to follow-up in blood pressure and transthoracic echocardiography (TTE) parameters. A multivariate logistic regression model was used to verify our aim.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 69 patients were finally included (51 on ACEI\/ARB and 18 on CCB). Both univariate analysis [odds ratio (OR) 0.241, 95% confidence interval (CI) 0.078\u20130.745] and multivariate analysis (OR: 0.246, 95% CI: 0.077\u20130.792) demonstrated that ACEI\/ARB were associated with a lower risk of NOAF compared to CCB. The mean reduction in left atrial diameter (LAD) from baseline was greater in ACEI\/ARB group than in CCB group (<jats:italic>P\u2009<\/jats:italic>=\u20090.034). There was no statistical difference between groups in blood pressure and other TTE parameters after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For patients with PPI combined with hypertension, ACEI\/ARB may be superior to CCB in selecting anti-hypertensive drugs, as ACEI\/ARB further reduces the risk of NOAF. One reason for this may be that ACEI\/ARB improves left atrial remodelling such as LAD better.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1191539","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T19:06:16Z","timestamp":1687547176000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of ACEI\/ARB or CCB use on atrial fibrillation in hypertensive patients following permanent pacemaker implantation"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhijie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaorong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.21037\/jtd-20-2913","article-title":"Analysis of postoperative complications and risk factors in patients with permanent pacemaker implantation","volume":"12","author":"Jing","year":"2020","journal-title":"J Thorac Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.11909\/j.issn.1671-5411.2018.10.008","article-title":"Analyses of risk factors and prognosis for new-onset atrial fibrillation in elderly patients after dual-chamber pacemaker implantation","volume":"15","author":"Chen","year":"2018","journal-title":"J Geriatr Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.118.035012","article-title":"Early risks of death, stroke\/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation","volume":"139","author":"Bassand","year":"2019","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e2014874","DOI":"10.1001\/jamanetworkopen.2020.14874","article-title":"Trends in atrial fibrillation incidence rates within an integrated health care delivery system, 2006\u20132018","volume":"3","author":"Williams","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.amjcard.2017.08.014","article-title":"Temporal trends in the incidence, prevalence, and survival of patients with atrial fibrillation from 2004 to 2016","volume":"120","author":"Williams","year":"2017","journal-title":"Am J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.jamda.2021.01.063","article-title":"Renin-angiotensin system inhibitors prognostic benefit in older patients with atrial fibrillation","volume":"22","author":"Cesp\u00f3n-Fern\u00e1ndez","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","article-title":"Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/ki.2015.96","article-title":"Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis","volume":"88","author":"Lin","year":"2015","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijcard.2007.05.012","article-title":"Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation","volume":"127","author":"Ozaydin","year":"2008","journal-title":"Int J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e3721","DOI":"10.1097\/MD.0000000000003721","article-title":"Angiotensin-receptor blocker, angiotensin-converting enzyme inhibitor, and risks of atrial fibrillation: a nationwide cohort study","volume":"95","author":"Hsieh","year":"2016","journal-title":"Medicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/0366-6999.189924","article-title":"Olmesartan reduces new-onset atrial fibrillation and atrial fibrillation burden after dual-chamber pacemaker implantation in atrioventricular block patients","volume":"129","author":"Zhang","year":"2016","journal-title":"Chin Med J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.eupc.2005.06.003","article-title":"Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?","volume":"7","author":"Williams","year":"2005","journal-title":"Europace"},{"key":"B13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2004.03.056","article-title":"Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation","volume":"44","author":"L'Allier","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6628469","DOI":"10.1155\/2021\/6628469","article-title":"Angiotensin receptor blocker and calcium channel blocker preventing atrial fibrillation recurrence in patients with hypertension and atrial fibrillation: a meta-analysis","volume":"2021","author":"Ma","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/europace\/euq439","article-title":"Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study)","volume":"13","author":"Yamashita","year":"2011","journal-title":"Europace"},{"key":"B16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.21037\/atm-21-1792","article-title":"Association of furosemide or hydrochlorothiazide use with risk of atrial fibrillation post pacemaker implantation among elderly patients","volume":"9","author":"Lin","year":"2021","journal-title":"Ann Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/157239","article-title":"Review of the epidemiology, pathogenesis and prevention of atrial fibrillation after pacemaker implantation","author":"Wu","year":"2023","journal-title":"Adv Clin Exp Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/ajh\/hpz077","article-title":"Hypertension and atrial fibrillation: epidemiological data, pathogenesis, and therapeutic implications","volume":"32","author":"Liatakis","year":"2019","journal-title":"Am J Hypertens"},{"key":"B19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41371-019-0279-7","article-title":"Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management","volume":"33","author":"Gumprecht","year":"2019","journal-title":"J Hum Hypertens"},{"key":"B20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00059-019-04869-z","article-title":"The risk factors of new-onset atrial fibrillation after pacemaker implantation","volume":"46","author":"Wu","year":"2021","journal-title":"Herz"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0209687","DOI":"10.1371\/journal.pone.0209687","article-title":"Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCRESAHA.120.316576","article-title":"A new therapeutic framework for atrial fibrillation drug development","volume":"127","author":"Ang","year":"2020","journal-title":"Circ Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cjca.2014.01.018","article-title":"A single fixed-dose combination for all patients is bad medicine","volume":"30","author":"Spence","year":"2014","journal-title":"Can J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/eurheartj\/ehi668","article-title":"Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence","volume":"27","author":"Ehrlich","year":"2006","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10741-019-09837-7","article-title":"Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?","volume":"25","author":"Mascolo","year":"2020","journal-title":"Heart Fail Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10286-018-0572-5","article-title":"The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications","volume":"29","author":"Miller","year":"2019","journal-title":"Clin Auton Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1124\/jpet.120.000150","article-title":"Angiotensin-(1-7) rescues chronic intermittent hypoxia-aggravated transforming growth factor-\u03b2-mediated airway remodeling in murine and cellular models of asthma","volume":"375","author":"Zhou","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e5594","DOI":"10.1590\/1414-431X20165594","article-title":"Angiotensin-(1-7) relieved renal injury induced by chronic intermittent hypoxia in rats by reducing inflammation, oxidative stress and fibrosis","volume":"50","author":"Lu","year":"2017","journal-title":"Braz J Med Biol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5582\/bst.2021.01461","article-title":"Association of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists use with risk of atrial fibrillation after pacemaker implantation among very old patients","volume":"15","author":"Lin","year":"2022","journal-title":"Biosci Trends"},{"key":"B30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lfs.2016.04.013","article-title":"Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44-hyaluronan interaction in rats with hypertension and myocardial fibrosis","volume":"153","author":"Bai","year":"2016","journal-title":"Life Sci"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1191539\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T19:06:20Z","timestamp":1687547180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1191539\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":30,"alternative-id":["10.3389\/fcvm.2023.1191539"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1191539","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"article-number":"1191539"}}